MB07133 gets orphan drug status

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

MB07133 gets orphan drug status

SAN DIEGO—Metabasis Therapeutics' MB07133 has received orphan drug status from FDA for the treatment of hepatocellular carcinoma. MB07133 is a novel HepDirect prodrug of cytarabine monophosphate designed to produce the oncolytically active form, cytarabine triphosphate, in the liver tumor where it acts to inhibit cell proliferation and induce apoptosis.

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Related Content